Last updated: 4 June 2024 at 4:18pm EST

Michael S. Iskra Net Worth

Mr. Michael S. Iskra biography

Michael S. Iskra is the Chief Commercial Officer at QuidelOrtho.

How old is Mr Iskra?

Mr Iskra is 51, he's been the Chief Commercial Officer of QuidelOrtho since . There are 24 older and 3 younger executives at QuidelOrtho. The oldest executive at QuidelOrtho Corporation is Mary Polan, 76, who is the Independent Director.

Insiders trading at QuidelOrtho

Over the last 21 years, insiders at QuidelOrtho have traded over 509,235,797$ worth of QuidelOrtho stock and bought 304,015 units worth 10,385,234$ . The most active insiders traders include Jack W Schuler、Matthew Strobeck、Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of 1,246,606$. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth 3,078,785$.

What does QuidelOrtho do?

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.

QuidelOrtho executives and stock owners

QuidelOrtho executives and other stock owners filed with the SEC include:

Douglas Bryant,
President, Chief Executive Officer, Director
Douglas C. Bryant,
Pres, CEO & Director
Randall Steward,
Chief Financial Officer
Michael Abney,
Senior Vice President - Distribution
Robert Bujarski,
Chief Operating Officer
Ratan Borkar,
Senior Vice President - International Commercial Operations
Werner Kroll,
Senior Vice President - R&D
Edward Russell,
Senior Vice President - Business Development
Robert J. Bujarski,
Chief Operating Officer
Randall J. Steward,
Chief Financial Officer
Dr. Werner Kroll,
Sr. VP of R&D
Ratan S. Borkar,
Sr. VP of International Commercial Operations
Robert J. Bujarski J.D.,
Pres & COO
Kenneth Buechler,
Independent Chairman of the Board
Edward Michael,
Independent Director
Ken Widder,
Independent Director
Charles Slacik,
Independent Director
Matthew Strobeck,
Independent Director
Mary Polan,
Independent Director
Kathy Ordonez,
Independent Director
Ruben Argueta,
Director - Investor Relations
Ann Rhoads,
Director
Karen Gibson,
Senior Vice President, Information Systems and Business Transformation
Dr. Chockalingam Palaniappan Ph.D.,
Chief Innovation Officer
Patrick E. Klein,
Chief Admin. Officer
Louise Brandy,
Chief Information Officer
Rhys de Callier,
VP of Strategy & Portfolio Management
Dr. Johannes Kehle,
Pres of AnDiaTec Division
Phillip S. Askim,
VP, Associate Gen. Counsel & Sec.
Michael S. Iskra,
Chief Commercial Officer
Joseph M. Busky CPA,
Chief Financial Officer
Karen C. Gibson,
Sr. VP of Digital Health Bus. Unit
Edward Keith Russell,
Sr. VP of Bus. Devel.
Michael Donald Abney Jr.,
Sr. VP of North American Sales & Distribution
Michelle A. Hodges,
Sr. VP & Gen. Counsel
Group Inc.Carlyle Holdings ...,
Thomas D Brown,
Director
Rodney F Dammeyer,
Director
John Tamerius,
Sr. VP - Clinical/Reg Affairs
Patrick Klein,
Chief Administrative Officer
Louise Brandy,
SVP, Chief Information Officer
Tamara A. Ranalli,
SVP, Molecular Bus. Unit
Mark W Smits,
SVP-Commercial Operations
Mark Pulido,
Director
John Matthew Radak,
Chief Financial Officer
Timothy Todd Stenzel,
Chief Science Officer
Scot M Mc Leod,
Sr. VP - Operations
Caren L Mason,
President and CEO
Jack W Schuler,
Director
Thomas James Foley,
Chief Technical Officer
David R. Scholl,
Senior Vice President
Richard C Iii Tarbox,
Sr. VP - Corporate Development
Matthew T Heindel,
Sr. VP - Global Sales & Mrktg
Douglas S Harrington,
Director
Faye Wattleton,
Director
Mark Paiz,
Senior Vice President
Thomas A Glaze,
Director
Paul E Landers,
Sr. V.P., CFO and Secretary
S Wayne Kay,
President & CEO
William J. Ferenczy,
SVP, Cardio/Metabolic Unit
Michael S. Iskra,
EVP & CCO
Christopher M Smith,
Director
Joseph D Jr. Wilkins,
Evelyn S Dilsaver,
Joseph M Busky,
Chief Financial Officer
James Prutow,
Michelle A. Hodges,
SVP, General Counsel